Preliminary immunoinformatics research for prediction the most immunogenic linear and conformational B-cell epitopes of 14-3-3 antigen in echinococcus granulosus  by Moghaddam, G. et al.
422 17th International Congress on Infectious Diseases / International Journal of Infectious Diseases 45S (2016) 1–477
Conclusion: Our results demonstrate that vaccination of camels
with MVA-S confers protects against MERS-CoV infection. In addi-
tion, induction of MVA speciﬁc antibody cross neutralize camelpox
virus, suggesting that MVA-MERS-S can be used as a dual vaccine
in dromedary camels.
http://dx.doi.org/10.1016/j.ijid.2016.02.898
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Background: Dengue is a mosquito-borne viral infection with
a very rapid global expansion during the last 50 years. This dis-
ease has become an important public health problem in Asia and
Latin America with over half the world’s population at risk1. Sanoﬁ
Pasteur is developing a recombinant, live, attenuated, tetravalent
dengue vaccine (CYD-TDV) for countries at-risk of dengue2. The
results from CYD-TDV trials are useful to observe the trends in
immunogenicity (GMT) titres across various countries.
OBJECTIVES: To assess immunogenicity titres after 3 doses of
CYD dengue vaccine in children, adolescents and adults up to 60
years by revisiting pre- and post-vaccination GMTs from Sanoﬁ
Pasteur CYD-TDV trials.
Methods&Materials: Dengue neutralizing antibody (Ab) levels
were assessed by a plaque neutralization test with a 50% endpoint
(PRNT50) for each serotype. In total, 25 clinical studies from Phase
I to Phase III have been included in the clinical development plan.
Of these 25 clinical studies, the integrated immunogenicity anal-
ysis presented here is based on results from 11 trials conducted
in 8 Asian countries (Philippines, Indonesia, Malaysia, Vietnam,
Thailand, Singapore, Australia, and India) and 6 Latin American
countries (Brazil, Colombia, Honduras, Mexico, Peru, and Puerto
Rico).
Results: Immune titres increased after 3 doses from baseline,
and higher GMTs were observed with increasing age and endemic-
ity in all countries considered at-risk of dengue. Further exploration
in older adults in Australia3 vaccinated with 3 doses of CYD-TDV,
revealed that both the 18-60 age group (N=655) and the 46-60 age
group (N=241) had similar GMTs which were higher than baseline.
Conclusion: Integrated analysis from CYD-TDV trials in chil-
dren, adolescents and adults up to 60 years of age showed a
consistent ﬁnding of higher GMTs in the vaccinated arm versus
control arm. Subjects who received 3 doses of CYD-TDV elicited
a balanced immune response against all four serotypes.
References: WHO Dengue factsheet No. 117 (updated May
2015) Guy B and al., Vaccine, 2011 Toressi et al, Vaccine, 2015
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Background: Cystic Echinococcosis (CE) is one of the most
important zoonosis parasite diseases which caused by the larval
stage of Echinococcus granulosus (Eg). The Eg14-3-3 protein is a
vaccine candidate antigen which exists in different development
stages of E. granulosus. The basement of vaccine design strate-
gies is identiﬁcation the most efﬁcacious epitopes of the antigen.
This study presents linear and conformational B cell epitopes of the
Eg14-3-3 antigen via computational tools.
Methods & Materials: The protoscoleces (PSC) of E. granulo-
sus was aspirated from infected lungs and livers of slaughtered
sheep (Tabriz, Iran) and then DNA samples were extracted. The
polymerase chain reaction (PCR) was performed using speciﬁc
primers (forward: ATGTCTTCTCTCAGTAAGCGCGA and reverse:
ATCGGCTTTCGGCGGTTCAG) and basing on the sequence in Gen-
Bank (Access No. AY942149). After sequencing the PCR products,
our regional Eg14-3-3 sequence was utilized (the sequence of our
local Eg14-3-3 shall be published soon). The linear B-cell epitopes
were predicted by Bepipred Linear Epitope Prediction algorithm
with threshold 0.35. The conformational B-cell epitopes were pre-
dicted using a sequence-based server named CBTOPE which uses
the support vector machine (SVM) threshold -0.3, and also the
three dimensional (3D) properties of the antigen such as, Rela-
tive SolventAccessibility, Number of TransmembraneDomains and
protein tertiary structure prediction. The structural details of Eg14-
3-3which are usable in the epitope-based vaccine design evaluated
via SCRATCH Protein Predictor.
Results: The Best linear B-cell epitopes were selected based
on their length (<9 amino acids) and score (highest), so that
the high scales consist of ATEVAEGDMQTT, DTLPEESYK, EQKHDG-
DAK and TGDERKQASDN. Based on CBTOPE algorithm ﬁve high
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score sequence were found as followed; YVAEFCTGDERKQASDN,
ELARKAFDDAVAELDTLPEESYKDA, SDAGDTDAAEPPKAD, YMAKL-
CEQCERYDEMVKA and LSVAYKNVVGAR, so that the bold and
underlined amino acids are conformational predicted epitopes.
Therefore using the 3D structural parameters the most promi-
nent conformational epitopes were YVAEFCTGDERKQASDN and
ELARKAFDDAVAELDTLPEESYKDA.
Conclusion: Generally, in current study the many different
aspects of Eg14-3-3 B-cell epitopes were analyzed so that achieved
data will give crucial details of Eg14-3-3 antigen for designing
the new generation of epitope-based vaccines against Echinococcus
granulosus.
http://dx.doi.org/10.1016/j.ijid.2016.02.900
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Background: Pneumococcal Vaccine -10 (PCV 10)was included
in the Expanded Program of immunization (EPI) in Sindh, Pakistan
in February 2013. PCV 10 is given as a three dose schedule at 6,
10 and 14 weeks of life with no catch-up currently offered. We
undertook this study immediately before the introduction of PCV
10 to establish baseline pneumococcal carriage in naso-pharynx of
children 3-12 months of age and 1 to 5 years of age in an urban
community and children 3-12 months of age in a rural community
in Sindh.
Methods & Materials: Baseline questionnaires were ﬁlled and
nasopharyngeal specimens were collected from a random sam-
ple of children. Samples were processed in a central laboratory in
Karachi using CDC standardized sequential multiplex PCR assay.
Serotypeswere then categorized into vaccine type andnon-vaccine
type.
Results: A total of 670 children were enrolled. Culture positiv-
ity rate for pneumococcus was 76% and 80% in the infant group in
Karachi and Matiari respectively and 80% for children 1 to 5 years
of age in Karachi. Prevalence of PCV 10 serotypes in infantswas 30%
and 23% in Karachi and Matiari. In the older age group in Karachi,
prevalencewas 24%.Most common serotypeswere 6A, 6B, 23F, 19A
and 18C (Table 1).
Pneumococcal carriage rates in Karachi and Matiari
Table 1
-Socio demographic and clinical characteristics of enrolled children
Distribution of vaccine type and non-vaccine type serotypes
in healthy children in Karachi and Matiari
Conclusion: This survey establishes thepre PCV10 introduction
vaccine andnon-vaccine serotype carriage rate in children in a rural
and urban community in Sindh. Annually planned surveys in the
same communities will inform change in carriage rate after the
introduction and uptake of PCV 10 in these communities.
http://dx.doi.org/10.1016/j.ijid.2016.02.901
